<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Igarashi KJ</submitter><funding>Cancer Research UK</funding><funding>NIDDK NIH HHS</funding><funding>NHLBI NIH HHS</funding><funding>Medical Research Council</funding><funding>NCI NIH HHS</funding><funding>Wellcome Trust</funding><pagination>3366-3377</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10345863</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>7(14)</volume><pubmed_abstract>Hematopoietic stem cells (HSCs) are a rare type of hematopoietic cell that can entirely reconstitute the blood and immune system after transplantation. Allogeneic HSC transplantation (HSCT) is used clinically as a curative therapy for a range of hematolymphoid diseases; however, it remains a high-risk therapy because of its potential side effects, including poor graft function and graft-versus-host disease (GVHD). Ex vivo HSC expansion has been suggested as an approach to improve hematopoietic reconstitution in low-cell dose grafts. Here, we demonstrate that the selectivity of polyvinyl alcohol (PVA)-based mouse HSC cultures can be improved using physioxic culture conditions. Single-cell transcriptomic analysis helped confirm the inhibition of lineage-committed progenitor cells in physioxi</pubmed_abstract><journal>Blood advances</journal><pubmed_title>Physioxia improves the selectivity of hematopoietic stem cell expansion cultures.</pubmed_title><pmcid>PMC10345863</pmcid><funding_grant_id>T32 CA196585</funding_grant_id><funding_grant_id>R01 DK116944</funding_grant_id><funding_grant_id>R01 HL147124</funding_grant_id><funding_grant_id>K99 HL150218</funding_grant_id><funding_grant_id>MC_UU_00016/18</funding_grant_id><pubmed_authors>Igarashi KJ</pubmed_authors><pubmed_authors>Gottgens B</pubmed_authors><pubmed_authors>Czechowicz A</pubmed_authors><pubmed_authors>Bridge KS</pubmed_authors><pubmed_authors>Ho PY</pubmed_authors><pubmed_authors>Chan YY</pubmed_authors><pubmed_authors>Kealy D</pubmed_authors><pubmed_authors>Hickey JW</pubmed_authors><pubmed_authors>Wilkinson AC</pubmed_authors><pubmed_authors>Khoo HM</pubmed_authors><pubmed_authors>Nakauchi H</pubmed_authors><pubmed_authors>Kucinski I</pubmed_authors><pubmed_authors>Nolan GP</pubmed_authors><pubmed_authors>Tan TK</pubmed_authors><pubmed_authors>Bhadury J</pubmed_authors><pubmed_authors>Niizuma K</pubmed_authors><pubmed_authors>Hsu I</pubmed_authors></additional><is_claimable>false</is_claimable><name>Physioxia improves the selectivity of hematopoietic stem cell expansion cultures.</name><description>Hematopoietic stem cells (HSCs) are a rare type of hematopoietic cell that can entirely reconstitute the blood and immune system after transplantation. Allogeneic HSC transplantation (HSCT) is used clinically as a curative therapy for a range of hematolymphoid diseases; however, it remains a high-risk therapy because of its potential side effects, including poor graft function and graft-versus-host disease (GVHD). Ex vivo HSC expansion has been suggested as an approach to improve hematopoietic reconstitution in low-cell dose grafts. Here, we demonstrate that the selectivity of polyvinyl alcohol (PVA)-based mouse HSC cultures can be improved using physioxic culture conditions. Single-cell transcriptomic analysis helped confirm the inhibition of lineage-committed progenitor cells in physioxi</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Jul</publication><modification>2026-06-02T12:03:29.193Z</modification><creation>2026-04-18T03:11:18.446Z</creation></dates><accession>S-EPMC10345863</accession><cross_references><pubmed>36809781</pubmed><doi>10.1182/bloodadvances.2023009668</doi></cross_references></HashMap>